Objective:

To estimate the effect of female sexuality due to the use of the contraceptive combination estradiol valerate / Dienogest against Ethinylestradiol / Drospirenone.

Material and methods:

A controlled, randomized, unblinded clinical trial was carried out on 174 women, between 18 and 39 years of age, who underwent two hormonal contraceptive options with estradiol valerate / Dienogest and ethinylestradiol / Drospirenone; in a private clinic in Armenia, Quindío, between 2013 and 2017. The female sexual function index (IFSF) was used to analyze the sexual function of the participating women; at the beginning, at six, at eighteen and thirty-six months after the start of the contraceptive.

Results:

At the end of the study, the contraceptive combination estradiol valerate / Dienogest was a less aggressive therapy in the alteration of the sexual response cycle of the users, while the ethinylestradiol / drospirenone combination significantly affects the desire and excitement with lower scores in the IFSF.

Conclusions:

The results indicate that the estradiol valerate / Dienogest combination affects the desire, arousal and IFSF score less than the ethinylestradiol / drospirenone combination.

        · abstract in Spanish     · text in English     · English ( pdf )